替莫唑胺联合多巴胺D2受体拮抗剂协同抑制胶质母细胞瘤细胞生长
本研究探讨替莫唑胺(TMZ)与多巴胺D2受体(DRD2)拮抗剂(氟哌啶醇或利培酮)联合应用对胶质瘤细胞的抑制作用。结果显示联合治疗较单药更显著抑制胶质瘤细胞增殖,并更显著增加DNA损伤标志物γH2AX水平。机制上DRD2拮抗剂可抑制ERK信号通路并阻断TMZ诱导的保护性自噬,从而增强TMZ细胞毒性。
要点
- TMZ联合DRD2拮抗剂对胶质瘤细胞增殖的抑制具有协同效应。
- 联合治疗较单用TMZ更显著增加DNA损伤标志物γH2AX水平。
- DRD2拮抗剂通过抑制ERK通路和阻断保护性自噬增强TMZ毒性。
核心结论
- TMZ与DRD2拮抗剂联合对抑制胶质瘤细胞生长具有协同效应。
- 该联合策略为增强恶性胶质瘤化疗效果提供了新思路。
研究设计与样本
- 研究在胶质瘤细胞中比较TMZ单药、DRD2拮抗剂单药及联合治疗的效应。
- DRD2拮抗剂选用氟哌啶醇或利培酮。
主要发现
- 联合治疗较单药治疗更显著抑制胶质瘤细胞增殖。
- 联合治疗较单用TMZ更显著增加γH2AX水平,而单用DRD2拮抗剂对γH2AX无影响。
- TMZ处理后U251胶质瘤细胞和胶质母细胞瘤干细胞中DRD2转录本表达显著升高。
- DRD2拮抗剂可抑制细胞外信号相关激酶信号通路并阻断TMZ诱导的保护性自噬。
临床怎么用
- 提示TMZ联合DRD2拮抗剂可能增强对胶质母细胞瘤的化疗效果。
- DRD2表达升高可能作为TMZ治疗后的适应性改变,联合靶向DRD2或可克服耐药。
局限性
- 研究为体外细胞实验,尚未提供临床疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The current standard treatment of malignant glioma is maximal resection followed by chemotherapy and radiotherapy. Temozolomide (TMZ) has been the first-line chemotherapeutic agent used, although to achieve a satisfactory clinical effect. TMZ chemoresistance could result from glioblastoma stem cells, which are critical for tumor initiation, recurrence, and therapeutic resistance and are potential targets. Moreover, signals mediated by the dopamine D2 receptor (DRD2) can positively regulate proliferation and tumorigenesis of glioma cells. RESULTS: To enhance TMZ's antitumor effect, we treated glioma cells with combinations of TMZ and DRD2 antagonists (DDRAs). The combined application of TMZ and DDRAs (haloperidol or risperidone) had synergistic effects and inhibited proliferation of glioma cells more significantly than did monotherapy. The combined treatment increased the levels of γH2AX (a marker of DNA damage) more significantly than did TMZ alone, although DDRAs alone had no effect on γH2AX levels. Moreover, the expression of DRD2 transcripts in U251 glioma cells and glioblastoma stem cells were significantly elevated after TMZ treatment, suggesting crosstalk between TMZ- and DRD2-mediated signaling. To explore the underlying mechanisms, we measured the expression of prosurvival proteins after treatment with either TMZ or DDRAs alone or combined. The results showed that DDRAs could inhibit the extracellular signal-related kinase signaling pathway and block TMZ-induced protective autophagy, which could explain why DDRAs increased the cytotoxicity of TMZ. CONCLUSIONS: We have provided evidence showing the synergistic effects of TMZ and DDRAs on suppressing glioma cell growth. Our study has provided novel insights on enhancing the effectiveness of chemotherapy against malignant glioma and eventually improving the clinical outcomes of patients with glioblastoma multiforme.
引用
- Liu Z, Jiang X, Gao L, et al. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. World Neurosurg. 2019. PMID: 31048057. doi:10.1016/j.wneu.2019.04.180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。